1.Polysomnographic Evaluation of Sleep Disorders in Essential Tremor and Essential Tremor Plus: A Comparison With Healthy Controls
Ravi Prakash SINGH ; Mythirayee S ; Doniparthi Venkata SESHAGIRI ; Gulshan KUMAR ; Rohan MOHALE ; Pramod Kumar PAL ; Bindu M KUTTY ; Jitender SAINI ; Nitish L KAMBLE ; Vikram HOLLA ; Ravi YADAV
Journal of Movement Disorders 2025;18(1):45-54
		                        		
		                        			 Objective:
		                        			To explore sleep patterns in individuals with essential tremor (ET) and essential tremor plus (ET-Plus) compared with healthy controls and assess differences between ET and ET-Plus, given the lack of established polysomnography (PSG) data on these groups and the potential for sleep disturbances to serve as clinical markers. 
		                        		
		                        			Methods:
		                        			We conducted a prospective cross-sectional study at National Institute of Mental Health and Neurosciences, Bengaluru, from November 2021 to August 2023 on 45 patients (26 ET, 19 ET-Plus) and 45 controls. Tremor severity was assessed using The Essential Tremor Rating Assessment Scale (TETRAS) and Fahn‐Tolosa‐Marin Clinical Rating Scale (FTMRS). Sleep symptoms were assessed via the Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, Mayo Sleep Questionnaire, restless legs syndrome questionnaire, Berlin questionnaire, Generalized Anxiety Disorder Scale 7, and Patient Health Questionnaire-9. All patients and controls underwent overnight video PSG. Sleep scoring was manually performed by a trained sleep research technician and the first author following the American Academy of Sleep Medicine (2017) guidelines, with data analyzed using R studio. 
		                        		
		                        			Results:
		                        			Compared with ET-Plus patients, ET patients had a younger onset age (46.8±11.1 years versus 30.8±16.7 years, respectively). Compared with ET patients, ET-Plus patients had higher TETRAS and FTMRS scores (p<0.005). Compared with controls, both ET patients and ET-Plus patients presented poorer sleep quality, excessive daytime sleepiness, rapid eye movement (REM) sleep behavior disorder, and restless legs syndrome symptoms. PSG findings supported these clinical observations, showing an elevated apnea‒hypopnea index, reduced total sleep time, prolonged REM latency, decreased sleep efficiency, increased N1 stage duration, and reduced N2/N3 durations and percentages in patients versus controls. 
		                        		
		                        			Conclusion
		                        			The study highlights significant sleep architecture abnormalities in both ET and ET-Plus patients compared with healthy controls, with no differences between the ET groups. 
		                        		
		                        		
		                        		
		                        	
2.Predictive accuracy of fecal calprotectin for histologic remission in ulcerative colitis
Arshdeep SINGH ; Arshia BHARDWAJ ; Riya SHARMA ; Bhavjeet Kaur KAHLON ; Ashvin Singh DHALIWAL ; Dharmatma SINGH ; Simranjeet KAUR ; Devanshi JAIN ; Namita BANSAL ; Ramit MAHAJAN ; Kirandeep KAUR ; Aminder SINGH ; Vikram NARANG ; Harpreet KAUR ; Vandana MIDHA ; Ajit SOOD
Intestinal Research 2025;23(2):144-156
		                        		
		                        			 Background/Aims:
		                        			Accurate assessment of disease activity is crucial for effective management and treatment of ulcerative colitis (UC). This study evaluated the correlation between clinical, endoscopic, and histologic measures of disease activity in UC.  
		                        		
		                        			Methods:
		                        			Clinical, biochemical, endoscopic, and histologic disease activity was studied in 347 patients with UC. Agreements among various histologic classification systems, namely the Geboes Score (GS), Continuous GS, Nancy Index (NI), and Robarts Histopathology Index (RHI), were analyzed. The predictive accuracy of fecal calprotectin (FC) for endoscopic and histologic remission was assessed.  
		                        		
		                        			Results:
		                        			We demonstrate a fair to moderate correlation between clinical, endoscopic, and histologic measures of disease activity in UC. There was a robust concordance among GS, Continuous GS, NI, and RHI in distinguishing between patients in histologic remission or activity. The NI detected 75% of patients who met the remission criteria according to the RHI, whereas the RHI identified all patients in remission as defined by the NI. FC levels below 150 μg/g had >70% accuracy in predicting endoscopic remission. FC levels below 150 μg/g showed ≥80% accuracy, and FC levels below 100 μg/g demonstrated ≥ 85% accuracy in predicting histologic remission, regardless of the scoring index applied. Elevated FC levels were associated with both acute and chronic inflammatory infiltrates in biopsy samples.  
		                        		
		                        			Conclusions
		                        			FC is a reliable predictor of histologic remission, with higher accuracy at lower thresholds. The GS, Continuous GS, NI, and RHI demonstrate comparable performance. FC could help stratify patients’ need for colonoscopy for the assessment of endoscopic and histologic remission. 
		                        		
		                        		
		                        		
		                        	
3.Predictive accuracy of fecal calprotectin for histologic remission in ulcerative colitis
Arshdeep SINGH ; Arshia BHARDWAJ ; Riya SHARMA ; Bhavjeet Kaur KAHLON ; Ashvin Singh DHALIWAL ; Dharmatma SINGH ; Simranjeet KAUR ; Devanshi JAIN ; Namita BANSAL ; Ramit MAHAJAN ; Kirandeep KAUR ; Aminder SINGH ; Vikram NARANG ; Harpreet KAUR ; Vandana MIDHA ; Ajit SOOD
Intestinal Research 2025;23(2):144-156
		                        		
		                        			 Background/Aims:
		                        			Accurate assessment of disease activity is crucial for effective management and treatment of ulcerative colitis (UC). This study evaluated the correlation between clinical, endoscopic, and histologic measures of disease activity in UC.  
		                        		
		                        			Methods:
		                        			Clinical, biochemical, endoscopic, and histologic disease activity was studied in 347 patients with UC. Agreements among various histologic classification systems, namely the Geboes Score (GS), Continuous GS, Nancy Index (NI), and Robarts Histopathology Index (RHI), were analyzed. The predictive accuracy of fecal calprotectin (FC) for endoscopic and histologic remission was assessed.  
		                        		
		                        			Results:
		                        			We demonstrate a fair to moderate correlation between clinical, endoscopic, and histologic measures of disease activity in UC. There was a robust concordance among GS, Continuous GS, NI, and RHI in distinguishing between patients in histologic remission or activity. The NI detected 75% of patients who met the remission criteria according to the RHI, whereas the RHI identified all patients in remission as defined by the NI. FC levels below 150 μg/g had >70% accuracy in predicting endoscopic remission. FC levels below 150 μg/g showed ≥80% accuracy, and FC levels below 100 μg/g demonstrated ≥ 85% accuracy in predicting histologic remission, regardless of the scoring index applied. Elevated FC levels were associated with both acute and chronic inflammatory infiltrates in biopsy samples.  
		                        		
		                        			Conclusions
		                        			FC is a reliable predictor of histologic remission, with higher accuracy at lower thresholds. The GS, Continuous GS, NI, and RHI demonstrate comparable performance. FC could help stratify patients’ need for colonoscopy for the assessment of endoscopic and histologic remission. 
		                        		
		                        		
		                        		
		                        	
4.Polysomnographic Evaluation of Sleep Disorders in Essential Tremor and Essential Tremor Plus: A Comparison With Healthy Controls
Ravi Prakash SINGH ; Mythirayee S ; Doniparthi Venkata SESHAGIRI ; Gulshan KUMAR ; Rohan MOHALE ; Pramod Kumar PAL ; Bindu M KUTTY ; Jitender SAINI ; Nitish L KAMBLE ; Vikram HOLLA ; Ravi YADAV
Journal of Movement Disorders 2025;18(1):45-54
		                        		
		                        			 Objective:
		                        			To explore sleep patterns in individuals with essential tremor (ET) and essential tremor plus (ET-Plus) compared with healthy controls and assess differences between ET and ET-Plus, given the lack of established polysomnography (PSG) data on these groups and the potential for sleep disturbances to serve as clinical markers. 
		                        		
		                        			Methods:
		                        			We conducted a prospective cross-sectional study at National Institute of Mental Health and Neurosciences, Bengaluru, from November 2021 to August 2023 on 45 patients (26 ET, 19 ET-Plus) and 45 controls. Tremor severity was assessed using The Essential Tremor Rating Assessment Scale (TETRAS) and Fahn‐Tolosa‐Marin Clinical Rating Scale (FTMRS). Sleep symptoms were assessed via the Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, Mayo Sleep Questionnaire, restless legs syndrome questionnaire, Berlin questionnaire, Generalized Anxiety Disorder Scale 7, and Patient Health Questionnaire-9. All patients and controls underwent overnight video PSG. Sleep scoring was manually performed by a trained sleep research technician and the first author following the American Academy of Sleep Medicine (2017) guidelines, with data analyzed using R studio. 
		                        		
		                        			Results:
		                        			Compared with ET-Plus patients, ET patients had a younger onset age (46.8±11.1 years versus 30.8±16.7 years, respectively). Compared with ET patients, ET-Plus patients had higher TETRAS and FTMRS scores (p<0.005). Compared with controls, both ET patients and ET-Plus patients presented poorer sleep quality, excessive daytime sleepiness, rapid eye movement (REM) sleep behavior disorder, and restless legs syndrome symptoms. PSG findings supported these clinical observations, showing an elevated apnea‒hypopnea index, reduced total sleep time, prolonged REM latency, decreased sleep efficiency, increased N1 stage duration, and reduced N2/N3 durations and percentages in patients versus controls. 
		                        		
		                        			Conclusion
		                        			The study highlights significant sleep architecture abnormalities in both ET and ET-Plus patients compared with healthy controls, with no differences between the ET groups. 
		                        		
		                        		
		                        		
		                        	
5.Predictive accuracy of fecal calprotectin for histologic remission in ulcerative colitis
Arshdeep SINGH ; Arshia BHARDWAJ ; Riya SHARMA ; Bhavjeet Kaur KAHLON ; Ashvin Singh DHALIWAL ; Dharmatma SINGH ; Simranjeet KAUR ; Devanshi JAIN ; Namita BANSAL ; Ramit MAHAJAN ; Kirandeep KAUR ; Aminder SINGH ; Vikram NARANG ; Harpreet KAUR ; Vandana MIDHA ; Ajit SOOD
Intestinal Research 2025;23(2):144-156
		                        		
		                        			 Background/Aims:
		                        			Accurate assessment of disease activity is crucial for effective management and treatment of ulcerative colitis (UC). This study evaluated the correlation between clinical, endoscopic, and histologic measures of disease activity in UC.  
		                        		
		                        			Methods:
		                        			Clinical, biochemical, endoscopic, and histologic disease activity was studied in 347 patients with UC. Agreements among various histologic classification systems, namely the Geboes Score (GS), Continuous GS, Nancy Index (NI), and Robarts Histopathology Index (RHI), were analyzed. The predictive accuracy of fecal calprotectin (FC) for endoscopic and histologic remission was assessed.  
		                        		
		                        			Results:
		                        			We demonstrate a fair to moderate correlation between clinical, endoscopic, and histologic measures of disease activity in UC. There was a robust concordance among GS, Continuous GS, NI, and RHI in distinguishing between patients in histologic remission or activity. The NI detected 75% of patients who met the remission criteria according to the RHI, whereas the RHI identified all patients in remission as defined by the NI. FC levels below 150 μg/g had >70% accuracy in predicting endoscopic remission. FC levels below 150 μg/g showed ≥80% accuracy, and FC levels below 100 μg/g demonstrated ≥ 85% accuracy in predicting histologic remission, regardless of the scoring index applied. Elevated FC levels were associated with both acute and chronic inflammatory infiltrates in biopsy samples.  
		                        		
		                        			Conclusions
		                        			FC is a reliable predictor of histologic remission, with higher accuracy at lower thresholds. The GS, Continuous GS, NI, and RHI demonstrate comparable performance. FC could help stratify patients’ need for colonoscopy for the assessment of endoscopic and histologic remission. 
		                        		
		                        		
		                        		
		                        	
6.Polysomnographic Evaluation of Sleep Disorders in Essential Tremor and Essential Tremor Plus: A Comparison With Healthy Controls
Ravi Prakash SINGH ; Mythirayee S ; Doniparthi Venkata SESHAGIRI ; Gulshan KUMAR ; Rohan MOHALE ; Pramod Kumar PAL ; Bindu M KUTTY ; Jitender SAINI ; Nitish L KAMBLE ; Vikram HOLLA ; Ravi YADAV
Journal of Movement Disorders 2025;18(1):45-54
		                        		
		                        			 Objective:
		                        			To explore sleep patterns in individuals with essential tremor (ET) and essential tremor plus (ET-Plus) compared with healthy controls and assess differences between ET and ET-Plus, given the lack of established polysomnography (PSG) data on these groups and the potential for sleep disturbances to serve as clinical markers. 
		                        		
		                        			Methods:
		                        			We conducted a prospective cross-sectional study at National Institute of Mental Health and Neurosciences, Bengaluru, from November 2021 to August 2023 on 45 patients (26 ET, 19 ET-Plus) and 45 controls. Tremor severity was assessed using The Essential Tremor Rating Assessment Scale (TETRAS) and Fahn‐Tolosa‐Marin Clinical Rating Scale (FTMRS). Sleep symptoms were assessed via the Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, Mayo Sleep Questionnaire, restless legs syndrome questionnaire, Berlin questionnaire, Generalized Anxiety Disorder Scale 7, and Patient Health Questionnaire-9. All patients and controls underwent overnight video PSG. Sleep scoring was manually performed by a trained sleep research technician and the first author following the American Academy of Sleep Medicine (2017) guidelines, with data analyzed using R studio. 
		                        		
		                        			Results:
		                        			Compared with ET-Plus patients, ET patients had a younger onset age (46.8±11.1 years versus 30.8±16.7 years, respectively). Compared with ET patients, ET-Plus patients had higher TETRAS and FTMRS scores (p<0.005). Compared with controls, both ET patients and ET-Plus patients presented poorer sleep quality, excessive daytime sleepiness, rapid eye movement (REM) sleep behavior disorder, and restless legs syndrome symptoms. PSG findings supported these clinical observations, showing an elevated apnea‒hypopnea index, reduced total sleep time, prolonged REM latency, decreased sleep efficiency, increased N1 stage duration, and reduced N2/N3 durations and percentages in patients versus controls. 
		                        		
		                        			Conclusion
		                        			The study highlights significant sleep architecture abnormalities in both ET and ET-Plus patients compared with healthy controls, with no differences between the ET groups. 
		                        		
		                        		
		                        		
		                        	
7.Clinical spectrum of elderly-onset inflammatory bowel disease in India
Yogesh Kumar GUPTA ; Arshdeep SINGH ; Vikram NARANG ; Vandana MIDHA ; Ramit MAHAJAN ; Varun MEHTA ; Dharmatma SINGH ; Namita BANSAL ; Madeline Vithya Barnaba DURAIRAJ ; Amit Kumar DUTTA ; Ajit SOOD
Intestinal Research 2023;21(2):216-225
		                        		
		                        			 Background/Aims:
		                        			Inflammatory bowel disease (IBD) is increasingly being recognized in elderly patients. Data on clinical spectrum of elderly-onset IBD patients is lacking from India. 
		                        		
		                        			Methods:
		                        			A cross-sectional retrospective analysis of a prospectively maintained database of patients diagnosed with IBD was conducted at 2 centers in India. The clinical spectrum of elderly-onset IBD including demographic profile (age and sex), clinical presentation, disease characteristics (disease behavior and severity, extent of disease), and treatment were recorded and compared with adult-onset IBD. 
		                        		
		                        			Results:
		                        			During the study period, 3,922 (3,172 ulcerative colitis [UC] and 750 Crohn’s disease [CD]) patients with IBD were recorded in the database. A total of 186 patients (4.74%; 116 males [62.36%]) had elderly-onset IBD (69.35% UC and 30.64% CD). Diarrhea, blood in stools, nocturnal frequency and pain abdomen were the commonest presentations for UC, whereas pain abdomen, weight loss and diarrhea were the most frequent symptoms in CD. For both elderly onset UC and CD, majority of the patients had moderately severe disease. Left-sided colitis was the commonest disease location in UC. Isolated ileal disease and inflammatory behavior were the most common disease location and behavior, respectively in CD. 5-Aminosalicylates were the commonest prescribed drug for both elderly onset UC and CD. Thiopurines and biologics were used infrequently. Prevalence of colorectal cancer was higher in elderly onset IBD. 
		                        		
		                        			Conclusions
		                        			Elderly onset IBD is not uncommon in India. Both the elderly onset UC and CD were milder, with no significant differences in disease characteristics (disease extent, location and behavior) when compared to adult-onset IBD. Colorectal cancer was more common in elderly onset IBD. 
		                        		
		                        		
		                        		
		                        	
8.Low prevalence of primary sclerosing cholangitis in patients with inflammatory bowel disease in India
Arshdeep SINGH ; Vandana MIDHA ; Vikram NARANG ; Saurabh KEDIA ; Ramit MAHAJAN ; Pavan DHOBLE ; Bhavjeet Kaur KAHLON ; Ashvin Singh DHALIWAL ; Ashish TRIPATHI ; Shivam KALRA ; Narender Pal JAIN ; Namita BANSAL ; Rupa BANERJEE ; Devendra DESAI ; Usha DUTTA ; Vineet AHUJA ; Ajit SOOD
Intestinal Research 2023;21(4):452-459
		                        		
		                        			 Background/Aims:
		                        			Primary sclerosing cholangitis (PSC) represents the most common hepatobiliary extraintestinal manifestation of inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD). Limited data exist on PSC in patients with IBD from India. We aimed to assess the prevalence and disease spectrum of PSC in Indian patients with IBD. 
		                        		
		                        			Methods:
		                        			Database of IBD patients at 5 tertiary care IBD centers in India were analyzed retrospectively. Data were extracted and the prevalence of PSC-IBD was calculated. 
		                        		
		                        			Results:
		                        			Forty-eight patients out of 12,216 patients with IBD (9,231 UC, 2,939 CD, and 46 IBD unclassified) were identified to have PSC, resulting in a prevalence of 0.39%. The UC to CD ratio was 7:1. Male sex and pancolitis (UC) or colonic CD were more commonly associated with PSC-IBD. The diagnosis of IBD preceded the diagnosis of PSC in most of the patients. Majority of the patients were symptomatic for liver disease at diagnosis. Eight patients (16.66%) developed cirrhosis, 5 patients (10.41%), all UC, developed malignancies (3 colorectal cancer [6.25%] and 2 cholangiocarcinoma [4.16%]), and 3 patients died (2 decompensated liver disease [4.16%] and 1 cholangiocarcinoma [2.08%]) on follow-up. None of the patients mandated surgical therapy for IBD. 
		                        		
		                        			Conclusions
		                        			Concomitant PSC in patients with IBD is uncommon in India and is associated with lower rates of development of malignancies. 
		                        		
		                        		
		                        		
		                        	
9.Perioperative complications of laparoscopic inguinal hernia repair in India: a prospective observational study
Vikram SAINI ; Amrutha VARSHINI R ; Yashwant Singh RATHORE ; Sunil CHUMBER ; Kamal KATARIA ; Richa GARG
Journal of Minimally Invasive Surgery 2023;26(4):190-197
		                        		
		                        			 Purpose:
		                        			These days laparoscopic inguinal hernia surgery, both totally extraperitoneal (TEP) and transabdominal preperitoneal (TAPP), is a commonly performed procedure due to advancements in laparoscopic instruments and the availability of skilled laparoscopic surgeons. The purpose of this study was to compare the perioperative complications of these two procedures. 
		                        		
		                        			Methods:
		                        			This was a prospective observational study between July 2019 and December 2020. Perioperative complications were compared with a 6-month follow-up. It included 144patients, of whom 71 underwent TAPP repair and 73 underwent TEP repair. The selection wasbased on the surgeon’s choice. 
		                        		
		                        			Results:
		                        			Early postoperative complications were scrotal edema (12 cases in TEP and 16 in TAPP), urinary retention (one case in TEP), ecchymosis (six cases in TEP and two in TAPP), and scrotal subcutaneous emphysema (two cases in TEP). On follow-up, seroma was found in a total of 22 cases, of which 12 were TEP and 10 were TAPP. While only one case of TAPP developed surgical site infection. There was no statistically significant difference in hospital stay between the two groups (p = 0.58). The pain scores significantly decreased throughout recovery and were comparable between the groups. Neither group experienced a recurrence during the 6-month follow-up. Fifty-eight patients developed Clavien-Dindo grade I complications, one had grade II, and three had grade IIIa complications. 
		                        		
		                        			Conclusion
		                        			With the increasing experience of the surgical fraternity in laparoscopic surgery, TEP and TAPP were proven to be comparable in terms of duration of surgery, postoperative complications, hospital stay, pain scores, and recurrence during the 6-month follow-up. 
		                        		
		                        		
		                        		
		                        	
10.AI-CoV Study: Autoimmune Encephalitis Associated With COVID-19 and Its Vaccines—A Systematic Review
MM SAMIM ; Debjyoti DHAR ; Sheetal GOYAL ; Treshita DEY ; Naznin PARVIN ; Rutul D. SHAH ; Vikram SINGH ; Sampurna CHOWDHURY ; Bhavesh Mohan LAL ; Nibu VARGHESE ; Abhishek GOHEL ; Abhishek CHOWDHURY ; Aritra CHATTERJEE ; Shahyan SIDDIQUI
Journal of Clinical Neurology 2022;18(6):692-710
		                        		
		                        			 Background:
		                        			and Purpose Autoimmune encephalitis (AIE) following coronavirus disease 2019 (COVID-19) is an underexplored condition. This study aims to systematically review the clinico-investigational and pathophysiologic aspects of COVID-19 and its vaccines in association with AIE, and identify the factors predicting neurological severity and outcomes. 
		                        		
		                        			Methods:
		                        			Relevant data sources were searched using appropriate search terms on January 15, 2022. Studies meeting the criteria for AIE having a temporal association with COVID-19 or its vaccines were included. 
		                        		
		                        			Results:
		                        			Out of 1,894 citations, we included 61 articles comprising 88 cases: 71 of COVID-19-associated AIE, 3 of possible Bickerstaff encephalitis, and 14 of vaccine-associated AIE.There were 23 definite and 48 possible seronegative AIE cases. Anti-NMDAR (N-methyl-D-aspartate receptor; n=12, 16.9%) was the most common definite AIE. Males were more commonly affected (sex ratio=1.63) in the AIE subgroup. The neurological symptoms included altered mental state (n=53, 74.6%), movement disorders (n=28, 39.4%), seizures (n=24, 33.8%), behavioural (n=25, 35.2%), and speech disturbances (n=17, 23.9%). The median latency to AIE diagnosis was 14 days (interquartile range=4–22 days). Female sex and ICU admission had higher risks of sequelae, with odds ratio (OR) of 2.925 (95% confidence interval [CI]=1.005–8.516) and 3.515 (95% CI=1.160–10.650), respectively. Good immunotherapy response was seen in 42/48 (87.5%) and 13/13 (100%) of COVID-19-associated and vaccine-associated AIE patients, respectively. Sequelae were reported in 22/60 (36.7%) COVID-19 associated and 10/13 (76.9%) vaccine-associated cases. 
		                        		
		                        			Conclusions
		                        			The study has revealed diagnostic, therapeutic, and pathophysiological aspects of AIE associated with COVID-19 and its vaccines, and its differences from postinfectious AIE.Systematic review registration PROSPERO registration number CRD42021299215 
		                        		
		                        		
		                        		
		                        	
            
Result Analysis
Print
Save
E-mail